Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 - PubMed (original) (raw)

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

R Aharoni et al. J Neuroimmunol. 1998.

Abstract

The synthetic amino acid copolymer, copolymer 1 (Cop 1) induces T suppressor (Ts) lines/clones, which are confined to the Th2 pathway, cross react with myelin basic protein (MBP), but not with other myelin antigens on the level of Th2 cytokine secretion. Nevertheless, Cop 1 Ts cells inhibited the IL-2 response of a proteolipid protein (PLP) specific line. Furthermore, Cop 1 Ts cells ameliorated EAE induced by two unrelated encephalitogenic epitopes of PLP: p139-151 and p178-191, that produced different forms of disease. This bystander suppression demonstrated by the Cop 1 Ts cells may explain the therapeutic effect of Cop 1 in EAE and MS.

PubMed Disclaimer

Similar articles

• Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.
  Aharoni R, Teitelbaum D, Sela M, Arnon R. Aharoni R, et al. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10821-6. doi: 10.1073/pnas.94.20.10821. Proc Natl Acad Sci U S A. 1997. PMID: 9380718 Free PMC article.
• Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.
  Aharoni R, Teitelbaum D, Arnon R, Sela M. Aharoni R, et al. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634-9. doi: 10.1073/pnas.96.2.634. Proc Natl Acad Sci U S A. 1999. PMID: 9892685 Free PMC article.
• Cop 1 as a candidate drug for multiple sclerosis.
  Teitelbaum D, Arnon R, Sela M. Teitelbaum D, et al. J Neural Transm Suppl. 1997;49:85-91. doi: 10.1007/978-3-7091-6844-8_9. J Neural Transm Suppl. 1997. PMID: 9266417 Review.
• Specific vaccines against autoimmune diseases.
  Sela M. Sela M. C R Acad Sci III. 1999 Nov;322(11):933-8. doi: 10.1016/s0764-4469(00)87189-9. C R Acad Sci III. 1999. PMID: 10646086 Review.

Cited by

• Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?
  Inyang KE, Folger JK, Laumet G. Inyang KE, et al. J Neuroimmune Pharmacol. 2021 Sep;16(3):531-547. doi: 10.1007/s11481-021-10000-z. Epub 2021 May 26. J Neuroimmune Pharmacol. 2021. PMID: 34041656 Review.
• The Evolving Mechanisms of Action of Glatiramer Acetate.
  Prod'homme T, Zamvil SS. Prod'homme T, et al. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249. Cold Spring Harb Perspect Med. 2019. PMID: 29440323 Free PMC article. Review.
• A Comprehensive Review on Copemyl®.
  Annovazzi P, Bertolotto A, Brescia Morra V, Gasperini C, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A. Annovazzi P, et al. Neurol Ther. 2017 Dec;6(2):161-173. doi: 10.1007/s40120-017-0079-3. Epub 2017 Jul 31. Neurol Ther. 2017. PMID: 28762192 Free PMC article. Review.
• Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.
  D Alessandro J, Garofalo K, Zhao G, Honan C, Duffner J, Capila I, Fier I, Kaundinya G, Kantor D, Ganguly T. D Alessandro J, et al. CNS Neurol Disord Drug Targets. 2017;16(6):714-723. doi: 10.2174/1871527316666170223162747. CNS Neurol Disord Drug Targets. 2017. PMID: 28240190 Free PMC article.
• Teriflunomide and its mechanism of action in multiple sclerosis.
  Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Bar-Or A, et al. Drugs. 2014 Apr;74(6):659-74. doi: 10.1007/s40265-014-0212-x. Drugs. 2014. PMID: 24740824 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal